KYNTRA BIO, INC.
Tremor tracks 2 of its cancer trials.
Company-wide warning signs
These add points to every one of this company's trials.
Trials
- KYNBKyntra Bio0Calm
A Study of FG-3246 in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Signing up patientsPhase 275 patientsMain results: Mar 31, 2028 - KYNBKyntra Bio0Calm
Evaluation of Efficacy and Safety of Neoadjuvant Treatment With Pamrevlumab in Combination With Chemotherapy (Either Gemcitabine Plus Nab-paclitaxel or FOLFIRINOX) in Participants With Locally Advanced, Unresectable Pancreatic Cancer
FinishedPhase 3284 patientsMain results: Jun 11, 2024
Key executives leaving
From the last 12 months of the company's SEC reports.
Insider trades (last 6 months)
“Insiders” are executives, board members, and big shareholders. Many of their sales are pre-planned: scheduled months ahead under a legal plan (called 10b5-1), so they usually say little. Tremor only counts sales that weren't pre-planned.
0 sales (0 not pre-planned) · 2 purchases
- Wettig ThaneCEO · May 14, 2026Bought 2,800 sharesabout $20 thousand ·
- Wettig ThaneCEO · May 14, 2026Bought 2,800 sharesabout $20 thousand ·
Recent SEC filings
Public companies must report important news and their finances to the SEC, the US agency that oversees the stock market.
- Warning about being removed from the stock exchangeNews report (8-K)Oct 6, 2026
- An executive or board member joined or leftNews report (8-K)Oct 1, 2026
- Signed a major agreement; Shared information with investorsNews report (8-K)Aug 31, 2026
- Quarterly reportQuarterly report (10-Q)Aug 13, 2026
- Shared quarterly resultsNews report (8-K)Aug 13, 2026